• Contracted Annual Recurring Revenue (CARR) of A$31.8M, up 15.6% on pcp
• Annual Recurring Revenue (ARR) Run Rate of A$25.1M, up 14.1% on pcp
• Sales orders of A$14.0M (TCV) in Q2 FY25

Mach7 Technologies Limited ('Mach7' or the 'Company') (ASX:M7T), a company specialising in innovative medical imaging software solutions, today provides a business update and quarterly cashflow report for the quarter ended 31 December 2024 (Appendix 4C). Mach7 CEO Mike Lampron said the company is on track to meet its FY25 guidance, delivering a solid result in Q2 FY25 as it signed new contracts with existing customers. Mach7 continued to make targeted investments in line with its three strategic pillars of cloud enablement, customer service, integration and interoperability. The company's products were showcased at over 10 booths at RSNA, resulting in a 78% increase in net new leads. Mach7 is in a strong financial position with no debt, growing cash balances and a disciplined approach to costs and cash management. The company announced an on-market share buy-back of up to A$5M, which it says illustrates its confidence in the future performance of Mach7.

Mach7 reaffirms its FY25 guidance for 15-25% growth in CARR and revenue on pcp and for opex growth to be less than revenue growth.

Looking ahead, the Company expects to see continued demand and volume growth from both new and existing customers across North America, APAC and the Middle East.